Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 11/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826194 | 1.00 | GLP1R (0.47) | GLP1RKMT2AACSS2MEN1KDM4E | |
| SCHEMBL30740849 | 0.85 | GLP1R (0.51) | GLP1RACSS2KDM4E | |
| SCHEMBL29825972 | 0.85 | GLP1R (0.51) | GLP1RACSS2KDM4E | |
| SCHEMBL22009801 | 0.82 | GLP1R (0.48) | GLP1RKMT2AACSS2 | |
| SCHEMBL30740795 | 0.81 | ACSS2 (0.46) | GLP1RACSS2KDM4EFNTAFNTB | |
| SCHEMBL29826815 | 0.81 | ACSS2 (0.46) | GLP1RACSS2KDM4EFNTAFNTB | |
| SCHEMBL24265338 | 0.81 | ACSS2 (0.46) | GLP1RACSS2KDM4EFNTAFNTB | |
| SCHEMBL30740718 | 0.81 | ACSS2 (0.46) | GLP1RACSS2KDM4EFNTAFNTB | |
| SCHEMBL22392102 | 0.80 | GLP1R (0.44) | GLP1RACSS2 | |
| SCHEMBL29826525 | 0.79 | GLP1R (0.46) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117043154-A | GPCR receptor agonists, pharmaceutical compositions comprising same, and methods of use thereof | 卡莫特医疗有限公司 | 2023-11-10 | — | — | CN | disclosed |